CIPLA

The Chemical, Industrial & Pharmaceutical Laboratories, now known as Cipla, was incorporated in 1935. And Khwaja Abdul Hamied is the founder of Cipla who gave the company all of his patent & proprietary formulas for several drugs and medicines, without charging any particular royalty. As on August 17, 1935, Cipla was also registered as a public limited company with an authorized capital of INR 6 lakhs.

It mainly focuses on the development of new formulations and also contains a wide range of pharmaceutical products and even offers prescription drugs, bulk drugs, animal products, and pesticides. It also deals in different types of food and beverages, baked foods, detergents, oral hygiene products, room fresheners, and personal care products, and much more. Approximately 55% of its overall income from its certain operations comes from overseas as it has 5,500 registered products in different countries. The Cipla offers drugs which are used for the treatment of cancer, Alzheimer's, arthritis, Parkinson, cardiovascular, and much more. It also provides medicines that prevent the transmission of AIDS from a mother to a child. It also offers various The Company offers consulting services on the preparation of products and materials, conducts plant evaluation, and supplies the plant equipment. It has set up the two institutes which are named as Dr. K. A Hamied Institute and the Cipla Cancer Palliative Care & Training Centre as well. It has its presence across 170 countries worldwide with various manufacturing units being approved by the regulatory authorities such as USFDA, WHO–Canada and MHRA–the UK, many others. The Cipla became the first company outside the US and Europe to launch the CFC or free inhalers. And in 2007, Cipla also launched an oral emergency contraceptive pill under the brand name as I–Pill and also launched a breakthrough screening technology in India. Also, the No-Touch Breast Scan or NTBS was the first ever painless, non–invasive, and radiation-free breast scanning technique for the detection of breast cancer at its initial stage. Then in 2009, it launched some of the generic versions of anti-flu drugs named oseltamivir and zanamivir in the local market to treat H1N1 influenza, which was spreading across the globe and especially in India. Later in 2010, the Piramal Healthcare Limited announced the signing of a definitive agreement with the Cipla Limited to purchase all the intellectual property rights in India related to 'i–pill' for an aggregate consideration of INR 95 crore.

The company also won the "Forbes Asia's Best under a Billion" in the list from the Forbes Magazine.

The Cipla also won the Most Profitable Company overall among its other competitors. Under a Billion in the Region and the Top 200 Small and Mid-Size companies from the Forbes Magazine.

1998– It launched the lamivudine and became one of the few companies in the world to offer all three component drugs of the retroviral combination therapy in which zidovudine and stavudine were already launched.

1999– Launches Nevirapine, an antiretroviral drug, used to prevent the transmission of AIDS from mother to child.